sorafenib eg 200 mg compr. pellic.
eg sa-nv - tosylate de sorafénib 274 mg - eq. sorafénib 200 mg - comprimé pelliculé - sorafenib
sunitinib eg 12.5 mg gél.
eg sa-nv - sunitinib 12,5 mg - gélule - sunitinib
sunitinib eg 25 mg gél.
eg sa-nv - sunitinib 25 mg - gélule - sunitinib
sunitinib eg 37.5 mg gél.
eg sa-nv - sunitinib 37,5 mg - gélule - sunitinib
sunitinib eg 50 mg gél.
eg sa-nv - sunitinib 50 mg - gélule - sunitinib
tadalafil eg 20 mg (pi pharma) compr. pellic.
pi pharma sa-nv - tadalafil 20 mg - comprimé pelliculé - tadalafil
zoledronate eg 4 mg/100 ml sol. perf. i.v. flac.
eg sa-nv - acide zolédronique monohydraté 42,6 µg/ml - eq. acide zolédronique 40 µg/ml - solution pour perfusion - zoledronic acid
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophtalmologiques - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
mirtazapine eg 15 mg (pi pharma) compr. pellic.
pi pharma sa-nv - mirtazapine 15 mg - comprimé pelliculé - mirtazapine
solifenacine/tamsulosine eg 6 mg - 0.4 mg compr. lib. modif.
eg sa-nv - succinate de solifénacine 6 mg - eq. solifénacine 4,53 mg; chlorhydrate de tamsulosine 0,4 mg - eq. tamsulosine 0,37 mg - comprimé à libération modifiée - tamsulosin and solifenacin